Drug intelligence / Profile preview

NOGA-102

Development stage: Unknown
Lead developer: NOGA Therapeutics

Overview

NOGA-102 is a drug candidate under development by Noga Therapeutics for the treatment of inflammatory bowel diseases. The specific mechanism of action, molecular target, and modality have not been disclosed in public sources as of June 2025. The drug is currently in the discovery phase, indicating it is at an early stage of preclinical research and has not yet entered clinical trials[1].

Brand names: NOGA-102NOGA102NOGA 102
Other names: NOGA-102NOGA102NOGA 102

Beyond the preview

Go deeper on NOGA-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOGA-102.

Explore the full profile